FDA
-
-
-
-
-
-
-
Kintor Pharma Announces 2021 Business Progress and Annual Results
-
-
-
-
-
-
-
Kintor Pharma Announces First Patient Dosing in Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized COVID-19 Patients in US
-
-
-
-
-
-
-
Kintor Announced (1) FDA Has Greenlighted Proxalutamide's Phase III Study for Hospitalized Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide's
-
-
-
-
-
324,381 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

